|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original Article |
1 Department of Haematology, Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 2XY, UK
2 Centro Andaluz de Biologia del Desarrollo, Universidad Pablo de Olavide, Seville, Spain
3 University of Massachusetts Medical School, Department of Pediatrics (Hematology/Oncology Division) and Department of Cancer Biology, LRB Room 403, 364 Plantation Street, Worcester MA 01605, USA
4 The Laboratory of Lymphocyte Signalling and Development, The Babraham Institute, Babraham, Cambridge, CB2 4AT, UK
* To whom correspondence should be addressed. E-mail: bg200{at}cam.ac.uk.
| Abstract |
|---|
Appropriate transcriptional regulation is critical for the biological functions of many key regulatory genes including the stem cell leukaemia (SCL) gene. As part of a systematic dissection of SCL transcriptional regulation, we have previously identified a 5245 bp SCL+18/19 enhancer, which targeted embryonic endothelium together with embryonic and adult haematopoietic progenitors and stem cells (HSCs). This enhancer is proving to be a powerful tool for manipulating haematopoietic progenitors and stem cells, but the design and interpretation of such transgenic studies requires a detailed understanding of enhancer activity in vivo. Here we demonstrate that the +18/19 enhancer is active in mast cells, megakaryocytes and adult endothelium. A 644 bp +19 core enhancer exhibited similar temporal and spatial activity to the 5245 bp +18/19 fragment, both during development and also in adult mice. Unlike the +18/19 enhancer, the +19 core enhancer was only active in adult mice when linked to the eukaryotic reporter gene human placental alkaline phosphatase. Activity of a single core enhancer in HSCs, endothelium, mast cells and megakaryocytes suggests possible overlaps in their respective transcriptional programmes. Moreover, activity in a proportion of thymocytes and other SCL-negative cell types suggests the existence of a silencer elsewhere in the SCL locus.
This article has been cited by other articles:
![]() |
A. M. Smith, M.-J. Sanchez, G. A. Follows, S. Kinston, I. J. Donaldson, A. R. Green, and B. Gottgens A novel mode of enhancer evolution: The Tal1 stem cell enhancer recruited a MIR element to specifically boost its activity Genome Res., September 1, 2008; 18(9): 1422 - 1432. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Sausville, A. A. Molinolo, X. Cheng, J. Frampton, N. Takebe, J. S. Gutkind, and R. A. Feldman RCAS/SCL-TVA Animal Model Allows Targeted Delivery of Polyoma Middle T Oncogene to Vascular Endothelial Progenitors In vivo and Results in Hemangioma Development Clin. Cancer Res., June 15, 2008; 14(12): 3948 - 3955. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-R. Landry, S. Kinston, K. Knezevic, M. F.T.R. de Bruijn, N. Wilson, W. T. Nottingham, M. Peitz, F. Edenhofer, J. E. Pimanda, K. Ottersbach, et al. Runx genes are direct targets of Scl/Tal1 in the yolk sac and fetal liver Blood, March 15, 2008; 111(6): 3005 - 3014. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ogilvy, R. Ferreira, S. G. Piltz, J. M. Bowen, B. Gottgens, and A. R. Green The SCL +40 Enhancer Targets the Midbrain Together with Primitive and Definitive Hematopoiesis and Is Regulated by SCL and GATA Proteins Mol. Cell. Biol., October 15, 2007; 27(20): 7206 - 7219. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Bockamp, C. Antunes, M. Maringer, R. Heck, K. Presser, S. Beilke, S. Ohngemach, R. Alt, M. Cross, R. Sprengel, et al. Tetracycline-controlled transgenic targeting from the SCL locus directs conditional expression to erythrocytes, megakaryocytes, granulocytes, and c-kit-expressing lineage-negative hematopoietic cells Blood, September 1, 2006; 108(5): 1533 - 1541. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. R. Mollica, J. T. B. Crawley, K. Liu, J. B. Rance, P. N. Cockerill, G. A. Follows, J.-R. Landry, D. J. Wells, and D. A. Lane Role of a 5'-enhancer in the transcriptional regulation of the human endothelial cell protein C receptor gene Blood, August 15, 2006; 108(4): 1251 - 1259. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Pimanda, L. Silberstein, M. Dominici, B. Dekel, M. Bowen, S. Oldham, A. Kallianpur, S. J. Brandt, D. Tannahill, B. Gottgens, et al. Transcriptional Link between Blood and Bone: the Stem Cell Leukemia Gene and Its +19 Stem Cell Enhancer Are Active in Bone Cells. Mol. Cell. Biol., April 1, 2006; 26(7): 2615 - 2625. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |
